Inactive Instrument

Press Releases XOMA Corp Nasdaq

Equities

US98419J1079

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	Apr. 25	AQ
XOMA : Acquisition/Asset Disposal - Form 8-K	Apr. 03	PU
XOMA Corporation Announces Closing of Tender Offer	Apr. 03	AQ
XOMA Declares Quarterly Preferred Stock Dividends	Mar. 21	AQ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	Mar. 19	AQ
Xoma: Q4 Earnings Snapshot	Mar. 08	AQ
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	Mar. 08	AQ
XOMA to Present at Upcoming Investor Conferences in March	Feb. 28	AQ
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	Feb. 19	AQ
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	Feb. 16	PR
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	Feb. 16	AQ
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	Jan. 19	AQ
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	Jan. 18	AQ
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C Results in XOMA Making a $1 Million Milestone Payment to LadRx	Jan. 12	AQ
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx	Jan. 11	AQ
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	Jan. 08	AQ
XOMA Announces Stock Repurchase Program of up to $50 Million	Jan. 02	AQ
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties	Dec. 20	AQ
XOMA Declares Quarterly Preferred Stock Dividends	Dec. 20	AQ
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties	Dec. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases XOMA Corp Nasdaq

Equities

US98419J1079

Press Releases

Filters